ArticleInternational journal of family medicine2015
Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice.
Article in International journal of family medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00120315 (Proton Pump Inhibitor Treatment Stop), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials.The British journal of general practice : the journal of the Royal College of General Practitioners · 2018Pooled it
- Deprescribing versus continuation of chronic proton pump inhibitor use in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Immediate discontinuation versus gradual tapering of proton pump inhibitors in long-term users: a randomized controlled trial.Journal of gastroenterology · 2026Trial
- Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial.BMC gastroenterology · 2022Trial
- Article
- Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review.Journal of clinical medicine · 2024Review
- Proton Pump Inhibitor Deprescription Prospective Study in Patients Without Indication: Are There Differences in Proportion of Restarts According to Withdrawal Strategy?The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023Article
- Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018.European journal of clinical pharmacology · 2022Article
- Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project.European journal of clinical pharmacology · 2021Article
- Feasibility of a pharmacy-led intervention to de-implement non-guideline-concordant proton pump inhibitor use.Implementation science communications · 2021Article
- Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic.Cureus · 2020Article
- Problems Associated with Deprescribing of Proton Pump Inhibitors.International journal of molecular sciences · 2019Review
- Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.Therapeutic advances in gastroenterology · 2016Article
- General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study.BMC family practice · 2016Article
- Outcome after Discontinuation of Proton Pump Inhibitors at a Residential Care Site: Quality Improvement Project.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. To investigate whether patients on long-term antisecretory medication need to continue treatment to control symptoms. Methods. A double-blinded randomised placebo-controlled trial in general practices in Denmark. Patients aged 18-90 who were treated with antisecretory drugs on a long-term basis were randomized to esomeprazole 40 mg or identical placebo. Outcome measures were time to discontinuation with trial medication due to failed symptom control analysed as survival data. The proportion of patients stopping trial medication during the one-year follow-up was estimated. Results. A total of 171 patients were included with a median prior duration of antisecretory treatment of four years (range: 0.5 to 14.6 years). 86 patients received esomeprazole 40 mg and 85 patients received placebo. At 12 months, statistically significantly more patients in the placebo group had discontinued (73% (62/85)) compared with the esomeprazole group (21% (18/86); p < 0.001). Conclusions. Long-term users of antisecretory drugs showed a preference for the active drug compared to placebo. However, 27% of patients continued on placebo throughout the study and did not need to reinstitute usual treatment. One in five patients treated with esomeprazole discontinued trial medication due to unsatisfactory symptom control. Discontinuation of antisecretory treatment should be considered in long-term users of antisecretory drugs. This trial is registered with Trial registration ClinicalTrials.gov ID: NCT00120315.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.